This study highlights the impact of other factors, such as sex difference, in the therapeutic effects that JAM-A blockade might promote in the development of tumors and demonstrates the complexity and challenges involved in the potential development of a JAM-A-targeted drug for cancer treatment. The gene discussed is F11R; the disease is cancer.